

# Hydrogen Sulfide as a Neuromodulator

**Hideo Kimura\***

*National Institute of Neuroscience, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8551, Japan*

## Abstract

Hydrogen sulfide (H<sub>2</sub>S) is a well-known toxic gas with the smell of rotten eggs. Since the first description of the toxicity of H<sub>2</sub>S in 1713, most studies about H<sub>2</sub>S have been devoted to its toxic effects. Recently, H<sub>2</sub>S has been proposed as a physiologically active messenger. Three groups discovered that the brain contains relatively high concentrations of endogenous H<sub>2</sub>S. This discovery accelerated the identification of an H<sub>2</sub>S-producing enzyme, cystathionine  $\beta$ -synthase (CBS) in the brain. In addition to the well-known regulators for CBS, S-adenosyl-L-methionine (SAM) and pyridoxal-5'-phosphate, it was recently found that Ca<sup>2+</sup>/calmodulin-mediated pathways are involved in the regulation of CBS activity. H<sub>2</sub>S is produced in response to neuronal excitation, and alters hippocampal long-term potentiation (LTP), a synaptic model for memory. can also regulate the release of corticotropin-releasing hormone (CRH) from hypothalamus. Another H<sub>2</sub>S producing enzyme, cystathionine  $\gamma$ -lyase (CSE), has been identified in smooth muscle, and H<sub>2</sub>S relaxes smooth muscle in synergy with nitric oxide (NO). Recent progress in the study of H<sub>2</sub>S as a novel neuromodulator/transmitter in the brain is briefly reviewed.

**Index Entries:** Hydrogen sulfide; neuromodulator; neurotransmitter; smooth muscle relaxant; cystathionine  $\beta$ -synthase; cystathionine  $\gamma$ -lyase; calmodulin.

## Introduction

Since the first description of H<sub>2</sub>S toxicity in 1713 (1), most studies about H<sub>2</sub>S have been devoted to its toxic effects with little attention paid to its physiological function (2). Warenycia

et al. found that the rat brain contains endogenous H<sub>2</sub>S (3), and endogenous concentrations of H<sub>2</sub>S have also been measured in human and bovine brain (4,5). The relatively high concentrations of H<sub>2</sub>S in the brain (50–160  $\mu$ M) suggest that it has a physiological function.

Endogenous H<sub>2</sub>S in the brain is formed from L-cysteine by a pyridoxal-5'-phosphate-dependent enzyme, cystathionine  $\beta$ -synthase (CBS) (6–11). CBS inhibitors, hydroxylamine

\* Address to which all correspondence and reprint requests should be sent. E-mail: kimura@ncnp.go.jp

Table 1  
Characteristics of H<sub>2</sub>S-producing Enzymes

	Cystathionine $\beta$ -synthase (CBS)	Cystathionine $\gamma$ -lyase (CSE)	References
Tissue localization	Brain, liver, kidney, ileum.	Thoracic aorta, ileum, portal vein, liver, kidney.	(10,11,44,49)
Activators	Pyridoxal 5'-phosphate S-adenosyl-L-methionine Ca <sup>2+</sup> /calmodulin	Pyridoxal 5'-phosphate	(6–11,26)
Inhibitors	Hydroxylamine Amino-oxyacetate	D,L-propargylglycine $\beta$ -cyano-L-alanine	(6,10,44)
Functional roles	H <sub>2</sub> S production in the brain	H <sub>2</sub> S production in smooth muscle	(10,11,44,49)

and amino-oxyacetate, suppress H<sub>2</sub>S production, while a CBS activator, S-adenosyl-L-methionine (SAM), enhances it. Observations with CBS knockout mice clearly show that CBS is the only enzyme that produces H<sub>2</sub>S in the brain (11).

Two other gases, nitric oxide (NO) and carbon monoxide (CO), are endogenously produced by enzymes localized to the brain. NO is synthesized by NO synthase via the metabolism of arginine to citrulline (12,13), and CO is produced by heme oxygenase via the metabolism of heme to biliverdin (14,15). Both NO and CO enhance the induction of hippocampal long-term potentiation (LTP), a synaptic model of learning and memory (16–22). The activities of NO synthase are regulated by Ca<sup>2+</sup>/calmodulin, and NO is released when N-methyl-D-aspartate (NMDA) receptors are activated by L-glutamate (23,24). In contrast, the regulation of CO production by neuronal excitation is not understood (22).

H<sub>2</sub>S production in the brain is enhanced in response to neuronal excitation via the Ca<sup>2+</sup> and calmodulin-mediated pathways (11). In addition, physiological concentrations of H<sub>2</sub>S specifically potentiate the activity of NMDA receptors, and hippocampal LTP is altered in CBS knockout mice (10,11). H<sub>2</sub>S can also regulate the release of corticotropin-releasing hormone from the hypothalamus (25). Based on these observations, it has been proposed that

H<sub>2</sub>S may function as a neuromodulator or transmitter in the brain (10,11). The following paragraphs outline the identification of an H<sub>2</sub>S-producing enzyme, CBS, in the brain and its regulation in response to neuronal excitation. The possible involvement of H<sub>2</sub>S in disease is also discussed.

### H<sub>2</sub>S-Producing Enzyme

The discovery of endogenous H<sub>2</sub>S in the brain prompted us to identify the enzyme that produces H<sub>2</sub>S. H<sub>2</sub>S can be formed from cysteine by pyridoxal-5'-phosphate-dependent enzymes, including CBS and CSE (6–9). Both CBS and CSE have been intensively studied in the liver and kidney, but little was known about them in the brain. CBS has recently been identified as a major H<sub>2</sub>S producing enzyme in the brain by the following observations: 1) CBS mRNA is highly expressed in the brain, especially in the hippocampus, while CSE mRNA is not detectable (10); 2) the production of H<sub>2</sub>S from brain homogenates is suppressed by CBS specific inhibitors hydroxylamine and aminooxyacetate, while it is not suppressed by CSE specific inhibitors D,L-propargylglycine and  $\beta$ -cyano-L-alanine; 3) a CBS activator, S-adenosyl-L-methionine (SAM), enhances the production of brain H<sub>2</sub>S (10); 4) endogenous H<sub>2</sub>S is under detectable levels in the brains of CBS knockout mice (11).




**A CBS and CSE****B CBS****C CSE**

Fig. 1. Cystathionine  $\beta$ -synthase (CBS) and cystathionine  $\gamma$ -lyase (CSE) catalyze two metabolic reactions. (A) is a common reaction for CBS and CSE to produce H<sub>2</sub>S. (B) is the specific reaction for CBS and C for CSE (6–9).

**Regulation of H<sub>2</sub>S Production**

CBS is dependent on pyridoxal 5'-phosphate and heme, and its activity is enhanced by SAM (26,27). No other regulators for this enzyme had been found. We have, however, recently shown that CBS activity is mediated by Ca<sup>2+</sup> and calmodulin (11). CBS activity is suppressed by calmodulin-specific inhibitors, W13 and trifluoroperazine, and CBS and calmodulin co-immunoprecipitate. The calmodulin-binding consensus sequence has also been identified in CBS (11,28). The enzymatic activity of CBS has two metabolic outcomes (6,29; Fig. 1). Most studies have been devoted to a pathway in which CBS catalyzes the reaction with substrate

homocysteine to produce cystathionine (29), but little attention has been paid to another pathway in which CBS produces H<sub>2</sub>S from L-cysteine as a substrate (6,10,11; Fig. 1A). SAM regulates CBS activity in both metabolic pathways (10,11,26), and a model for CBS regulation by SAM has been proposed (30). A similar mechanism may also function in the regulation of CBS by Ca<sup>2+</sup>/calmodulin (11; Fig. 2). In the absence of Ca<sup>2+</sup>/calmodulin the carboxy-terminal domain may cover the catalytic domain, and CBS activity remains at a basal level. When Ca<sup>2+</sup>/calmodulin binds to the 19 amino acid calmodulin binding consensus sequence, the catalytic domain is exposed by opening of the carboxy-terminal domain and CBS becomes active (Fig. 2). This model is supported by the observation that the CBS mutant (1–396), which is deficient in the 19 amino acid Ca<sup>2+</sup>/calmodulin binding sequence, is constantly active even in the absence of Ca<sup>2+</sup>/calmodulin (11; Fig. 2).

When neuronal cells are excited by an excitatory neurotransmitter glutamate, as well as electrical stimulation, H<sub>2</sub>S production is increased (11; Fig. 3). H<sub>2</sub>S production is not simply increased linearly in response to neuronal excitation, for there is a regulatory mechanism to maintain the production of H<sub>2</sub>S levels within nontoxic levels. For example, longer stimulation by glutamate or electrical activity, and greater concentrations of the Ca<sup>2+</sup> ionophore A23187, do not effectively increase H<sub>2</sub>S production (11).

**Regulation of Synaptic Activity by H<sub>2</sub>S**

What is the function of H<sub>2</sub>S in the brain? Physiological concentrations of H<sub>2</sub>S modify LTP, and LTP is altered in the brains of CBS knockout mice (10,11). In contrast, concentrations of H<sub>2</sub>S greater than the physiological basal level specifically suppress excitatory postsynaptic potentials (EPSPs) (10). This suppression was initially thought to be due to the toxic effect of H<sub>2</sub>S. However, H<sub>2</sub>S production can be locally and transiently increased in response to neuronal excitation, and the suppression of EPSPs still occurs (10,11).




Fig. 2. The regulation of CBS activity by  $\text{Ca}^{2+}$  and calmodulin. CBS consists of domains for heme binding (Heme), pyridoxal-5'-phosphate binding (PLP), catalytic,  $\text{Ca}^{2+}$  and calmodulin binding ( $\text{Ca}^{2+}/\text{CaM}$ ) and S-adenosyl-L-methionine binding (SAM). A model for CBS regulation by SAM has been proposed (30). A similar mechanism may also function in the regulation of CBS by  $\text{Ca}^{2+}$  calmodulin. In the absence of  $\text{Ca}^{2+}$ /calmodulin the carboxyl-terminal domain may cover the catalytic domain, and CBS activity remains at a basal level. When  $\text{Ca}^{2+}$ /calmodulin binds to the 19 amino acid sequence (amino acids 396–415), the catalytic domain is exposed by opening of the carboxy-terminal domain and CBS becomes active. This model is supported by our observation that the CBS mutant (1–396), which is deficient in the 19 amino acid  $\text{Ca}^{2+}$ /calmodulin binding sequence, is constantly active even in the absence of  $\text{Ca}^{2+}$ /calmodulin (11).

Because  $\text{H}_2\text{S}$  regulates the release of corticotropin-releasing hormone (CRH) from hypothalamus (25,31), it is possible that  $\text{H}_2\text{S}$  may modify the release of neurotransmitters. Therefore the effect of  $\text{H}_2\text{S}$  on glutamate receptor activation was examined, and it was shown that physiological concentrations of  $\text{H}_2\text{S}$  specifically enhance NMDA receptor-mediated responses (10). This modification of NMDA receptor activity by  $\text{H}_2\text{S}$  may not be the direct effect of  $\text{H}_2\text{S}$ , but may partly be due to the activation of cAMP pathways by  $\text{H}_2\text{S}$  (32). The NMDA receptor subunits have specific sites directly phosphorylated by protein kinase A, and  $\text{H}_2\text{S}$  may activate this pathway (33,34). It is not clear at present whether or not there is an effect of  $\text{H}_2\text{S}$  on glutamate release.

### ***Involvement of $\text{H}_2\text{S}$ in Diseases of the Nervous System***

There is a good amount of data that suggests that defects in  $\text{H}_2\text{S}$  metabolism may be involved in CNS disease. The CBS gene is encoded on chromosome 21q22.3 (35,36), a region associated with Down syndrome (37,38), and it has been proposed that  $\text{H}_2\text{S}$  may be involved in the cognitive dysfunction associated with Down syndrome (39). Loss of CBS activity causes homocystinuria, an autosomal recessive disease characterized, in part, by mental retardation (29). CBS interacts with Huntingtin, mutants of which cause Huntington's disease (40). Finally polymorphisms of CBS gene is significantly underrepresented in children with high IQ compared with those with average IQ, suggesting that CBS activity may be involved in the cognitive function (41). These observations in conjunction with the findings described earlier suggest that CBS and its product  $\text{H}_2\text{S}$  may regulate some aspects of synaptic activity and modify cognitive function.

Recent studies have shown that abnormalities in the cerebral microvasculature are relevant to the cause of dementia, including Alzheimer's disease (42,43). Although CBS is the major, if not exclusive, enzyme-producing




Fig. 3. Production and function of H<sub>2</sub>S in the central nervous system. When the electrical signals descend to the axon terminal, Ca<sup>2+</sup> enters into the nerve terminal and interacts with calmodulin. The Ca<sup>2+</sup>/calmodulin activates CBS to produce H<sub>2</sub>S. H<sub>2</sub>S can pass through the membrane and reach the postsynaptic membrane to modify the activity of the NMDA receptor, allowing greater Ca<sup>2+</sup> influx. H<sub>2</sub>S also can modulate the release of transmitters and hormones (10,25,31). When the NMDA receptor is activated, Ca<sup>2+</sup> enters through NMDA receptors and Ca<sup>2+</sup>/calmodulin activates CBS to produce H<sub>2</sub>S. H<sub>2</sub>S can regulate NMDA receptor activity and modulate the induction of LTP (10,11).

H<sub>2</sub>S in the brain, another H<sub>2</sub>S-producing enzyme, CSE, was identified as the major H<sub>2</sub>S-producing enzyme in the smooth muscle (44). Although exogenously applied H<sub>2</sub>S alone relaxes smooth muscle, much lower concentrations of H<sub>2</sub>S greatly enhance the smooth muscle relaxation induced by NO (44). H<sub>2</sub>S also hyperpolarizes smooth muscle by activating K<sub>ATP</sub> channels. (45). Based on these observations, it is likely that H<sub>2</sub>S may also regulate cerebral blood flow.

## Conclusions

The physiological relevance of two H<sub>2</sub>S-producing enzymes, CBS and CSE has been identified, and the regulation of their activities has also been determined. A novel finding that H<sub>2</sub>S production by CBS is regulated by Ca<sup>2+</sup> and calmodulin lead to the observation that H<sub>2</sub>S is produced in response to neuronal excitation. Exogenously applied H<sub>2</sub>S modifies LTP, and

LTP is altered in the brain of CBS knockout mice. H<sub>2</sub>S can regulate some aspects of synaptic activity and modify cognitive function. In smooth muscle, H<sub>2</sub>S enhances NO induced relaxation and can regulate the activity of CSE. Both gaseous smooth muscle relaxants strongly interact with each other.

A few candidates of molecular targets for H<sub>2</sub>S have been identified. These are NMDA receptors in the brain and the K<sub>ATP</sub> channel in smooth muscle (10,32,45). The mechanism of the activation of these targets has not been solved, and it is not known if it is a direct or indirect effect. Because H<sub>2</sub>S is a very active molecule, more targets are expected to be found. After H<sub>2</sub>S stimulates its targets, it has to be cleared from its site of action. The mechanism of clearance is not understood. The study of H<sub>2</sub>S as a physiologically active molecule has just beginning, but understanding the mechanisms underlying its physiological function may provide a new insights into neurotransmission.



## Acknowledgment

I thank Dr. D. Schubert for the critical reading of the manuscript. I also thank Ms. Y. Okuyama for preparation of figures. This work was supported by grant from the National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan.

## References

- Ramazzini B. (1713) Diseases of Workers (Translated from the Latin text *De Morbis Artificum* by W. C. Wright, 1940) University of Chicago Press, Chicago, IL. (Reprinted ed 1964 in *History Med.*, Vol. 23.)
- Reiffenstein R. J., Hulbert W. C., and Roth S. H. (1992) Toxicology of hydrogen sulfide. *Annu. Rev. Pharmacol. Toxicol.* **32**, 109–134.
- Warenycia M. W., Goodwin L. R., Benishin C. G., Reiffenstein R. J., Francom D. M., Taylor J. D., and Dieken F. P. (1989) Acute hydrogen sulfide poisoning: demonstration of selective uptake of sulfide by the brainstem by measurement of brain sulfide levels. *Biochem. Pharmacol.* **38**, 973–981.
- Goodwin L. R., Francom D., Dieken F. P., Taylor J. D., Warenycia M. W., Reiffenstein R. J., and Dowling G. (1989) Determination of sulfide in brain tissue by gas dialysis/ion chromatography: postmortem studies and two case reports. *J. Anal. Toxicol.* **13**, 105–109.
- Savage J. C. and Gould D. H. (1990) Determination of sulfides in brain tissue and rumen fluid by ion-interaction reversed-phase high-performance liquid chromatography. *J. Chromatogr.* **526**, 540–545.
- Stipanuk M. H. and Beck P. W. (1982) Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. *Biochem. J.* **206**, 267–277.
- Griffith O. W. (1987) Mammalian sulfur amino acid metabolism: an overview, in *Methods in enzymology*, (Jakoby W. B. and Griffith O. W., eds.) Vol. 143 Academic, New York: pp. 366–376.
- Erickson P. F., Maxwell I. H., Su L. J., Baumann M., and Glode L. M. (1990) Sequence of cDNA for rat cystathionine  $\gamma$ -lyase and comparison of deduced amino acid sequence with related *Escherichia coli* enzymes. *Biochem. J.* **269**, 335–340.
- Swaroop M., Bradley K., Ohura T., Tahara T., Roper M. D., Rosenberg L. E., and Kraus J. P. (1992) Rat cystathionine  $\beta$ -synthase. *J. Biol. Chem.* **267**, 11455–11461.
- Abe K. and Kimura H. (1996) The possible role of hydrogen sulfide as an endogenous neuromodulator. *J. Neurosci.* **16**, 1066–1071.
- Eto K., Ogasawara M., Umemura K., Nagai Y. and Kimura H. (2002) Hydrogen sulfide is produced in response to neuronal excitation. *J. Neurosci.* **22**, 3386–3391.
- Palmer R. M. J., Ashton D. S., and Moncada S. (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. *Nature* **333**, 664–666.
- Bredt D. S. and Snyder S. H. (1992) Nitric oxide, a novel neuronal messenger. *Neuron* **8**, 3–11.
- Maines M. D. (1988) Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. *FASEB J.* **2**, 2557–2568.
- Verma A., Hirsch D. J., Glatt C. E., Ronnett G. V., and Snyder, S. H. (1993) Carbon monoxide: a putative neural messenger. *Science* **259**, 381–384.
- O'Dell T. J., Hawkins R. D., Kandel E. R., and Arancio O. (1991) Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. *Proc. Natl. Acad. Sci. USA* **88**, 11285–11289.
- Schuman E. M. and Madison D. V. (1991) A requirement for the intercellular messenger nitric oxide in long-term potentiation. *Science* **254**, 1503–1506.
- Haley J. E., Wilcox G. L., and Chapman P. F. (1992) The role of nitric oxide in hippocampal long-term potentiation. *Neuron* **8**, 211–216.
- Stevens C. F. and Wang Y. (1993) Reversal of long-term potentiation by inhibitors of haem oxygenase. *Nature* **364**, 147–149.
- Zhuo M., Small S. A., Kandel E. R., and Hawkins R. D. (1993) Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus. *Science* **260**, 1946–1950.
- Bliss T. V., and Collingridge G. L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. *Nature* **361**, 31–39.
- Snyder S. H. and Ferris C. D. (2000) Novel neurotransmitters and their neuropsychiatric relevance. *Am. J. Psychiatry* **157**, 1738–1751.
- Garthwaite J., Charles S. L., and Chess-Williams R. (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors sug-

- gests role as intercellular messenger in the brain. *Nature* **336**, 385–388.
24. Bredt D. S. and Snyder S. H. (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. *Proc. Natl. Acad. Sci. USA* **87**, 682–685.
  25. Russo C. D., Tringali G., Ragazzoni E., Maggiano N., Menini E., Vairano M., et al. (2000) Evidence that hydrogen sulphide can modulate hypothalamo-pituitary-adrenal axis function: *in vitro* and *in vivo* studies in the rat. *J. Neuroend.* **12**, 225–233.
  26. Finkelstein J. D., Kyle W. E., Martin J. J., and Pick A. M. (1975) Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. *Biochem. Biophys. Res. Commun.* **66**, 81–87.
  27. Kery V., Bukovska G., and Kraus J. P. (1994) Transsulfuration depends on heme in addition to pyridoxal 5'-phosphate. *J. Biol. Chem.* **269**, 25283–25288.
  28. Rhoads A. R. and Friedberg F. (1997) Sequence motifs for calmodulin recognition. *FASEB J.* **11**, 331–340.
  29. Mudd S. H., Levy H. L., and Skovby F. (1989) Disorders of transsulfuration, in *The Metabolic Basis of Inherited Disease* (Scriver C. R., Beaudet A. L., Sly W. S., Valle D., eds.) McGraw-Hill, New York, pp 693–734.
  30. Shan X., Dunbrack R. L. J., Christopher S. A., and Kruger W. D., (2001) Mutation in the regulatory domain of cystathionine  $\beta$ -synthase can functionally suppress patient-derived mutations in cis. *Human Mol. Genet.* **10**, 635–643.
  31. Navarra P., Dello Russo C., Mancuso C., Preziosi P., and Grossman A. (2000) Gaseous neuromodulator in the control of neuroendocrine stress axis. *Ann. NY. Acad. Sci.* **917**, 638–646.
  32. Kimura H. (2000) Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. *Biochem. Biophys. Res. Comm.* **267**, 129–133.
  33. Leonard A. S. and Hell J. W. (1997) Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. *J. Biol. Chem.* **272**, 12107–12115.
  34. Tingley W. G., Ehlers M. D., Kameyama K., Doherty C., Ptak J. B., Riley C. T., and Haganir R. L. (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. *J. Biol. Chem.* **272**, 5157–5166.
  35. Skovby F., Krassikoff N., and Francke U. (1984) Assignment of the gene for cystathionine beta-synthase to human chromosome 21 in somatic cell hybrids. *Hum. Genet.* **65**, 291–294.
  36. Munke M., Kraus J. P., Ohura T., and Francke, U. (1988) The gene for cystathionine beta-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17. *Am. J. Hum. Genet.* **42**, 550–559.
  37. Korenberg J. R., Kawashima H., Pulst S. M., Ikeuchi T., Ogasawara N., Yamamoto, et al. (1990) Molecular definition of a region of chromosome 21 that causes features of the down syndrome phenotype. *Am. J. Hum. Genet.* **47**, 236–246.
  38. Kraus J. P. (1990) Molecular analysis of cystathionine  $\beta$ -synthase-a gene on chromosome 21. *Prog. Clin. Biol. Res.* **360**, 201–214.
  39. Kamoun P. (2001) Mental retardation in Down syndrome: a hydrogen sulfide hypothesis. *Med. Hypotheses* **57**, 389–392.
  40. Boutell J. M., Wood J. D., Harper P. S., and Jones A. L. (1998) Huntingtin interacts with cystathionine  $\beta$ -synthase. *Human Mol. Genet.* **7**, 371–378.
  41. Barbaux S., Plomin, R., and Whitehead A. S. (2000) Polymorphisms of genes controlling homocysteine/folate metabolism and cognitive function. *NeuroReport* **11**, 1133–1136.
  42. Kalaria R. N. (2000) The role of cerebral ischemia in Alzheimer's disease. *Neurobiol. Aging* **21**, 321–330.
  43. De la Torre J. C. and Mussivand T. (1993) Can disturbed brain microcirculation cause Alzheimer's disease? *Neurol. Res.* **15**, 146–153.
  44. Hosoki R., Matsuki N., and Kimura H. (1997) The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem. Biophys. Res. Commun.* **237**, 527–531.
  45. Zhao W., Zhang J., Lu Y., and Wang R. (2001) The vasorelaxant effect of H<sub>2</sub>S as a novel endogenous gaseous KATP channel opener. *EMBO J.* **20**, 6008–6016.